Triton: A Comparison of [Prasugrel] CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention TIMI-38

Study of:
A comparison of the experimental drug Prasugrel versus Clopidogrel (Plavix), an approved drug, in patients with Acute Coronary Syndrome (ACS) undergoing Percutaneous Coronary Intervention (PCI).

The purpose of this study is to compare the experimental drug Prasugrel versus Clopidogrel (Plavix), an approved drug, in patients with Acute Coronary Syndrome (ACS) undergoing Percutaneous Coronary Intervention (PCI). Both medications are anti-platelet drugs to reduce the chance of blood clots forming after receiving a coronary stent. Patients will take two tablets of study drug per day for the length of the study. Follow-up visits include blood draws and ECGs will be done at baseline, 30, 90, and 180, 270, 360, and 450 days after the start of the study.

James D. Madison, MD, FACC

M. Nicholas Burke, MD

Ivan J. Chavez, MD, FACC

Timothy D. Henry, MD, FACC 

Daniel Lips, MD, FACC

Michael R. Mooney, MD, FACC

Wesley R. Pedersen, MD, FACC

Anil K. Poulose, MD, FACC

Jay H. Traverse, MD, FACC, FAHA

Yale Wang, MD, FACC, FSCAI

Holly MacDonald, RN

For more information about this study or the Interventional Cardiology Research program at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124.